| 1 |
Balkwill F， Charles KA， Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell， 2005，7（3）：211-217.
|
| 2 |
Colotta F， Allavena P， Sica A， et al. Cancer-related inflammation， the seventh hallmark of cancer： links to genetic instability. Carcinogenesis， 2009，30（7）：1073-1081.
|
| 3 |
Lu SL， Reh D， Li AG， et al. Overexpression of transforming growth factor beta1 in head and neck epithelia results in inflammation， angiogenesis， and epithelial hyperproliferation.Cancer Res， 2004，64（13）：4405-4410.
|
| 4 |
Rhodus NL， Cheng B， Myers S， et al. The feasibility of monitoring NF-kappaB associated cytokines： TNF-alpha， IL-1 alpha， IL-6， and IL-8 in whole saliva for the malignant transformation of oral lichen planus. Mol Carcinog， 2005，44（2）：77-82.
|
| 5 |
Dudás J， Fullár A， Bitsche M， et al. Tumor-produced， active Interleukin-1β regulates gene expression in carcinoma associated fibroblasts. Exp Cell Res， 2011，317（15）：2222-2229.
|
| 6 |
Ralhan R， Desouza LV， Matta A， et al. iTRAQmultidimensional liquid chromatography and tandem mass spectrometry-based identification of potential biomarkers of oral epithelial dysplasia and novel networks between inflammation and premalignancy. J Proteome Res， 2009，8（1）：300-309.
|
| 7 |
Banerjeen AG， Bhattacharyya I， Vishwanatha JK， et al.Identification of genes and molecular pathways involved in the progression of premalignant oral epithelia. Mol Cancer Ther，2005，4（6）：865-875.
|
| 8 |
Apte RN， Dotan S， Elkabet M， et al. The involvement of IL-1 in tumorigenesis， tumor invasiveness， metastasis and tumor-host interactions. Cancer Metastasis Rev， 2006，25（3）：387-408.
|
| 9 |
Maxwell PJ， Gallagher R， Seaton A， et al. HIF-1 and NFkappaB-mediated upregulation of CXCR1 and CXCR2 expression promotes cell survival in hypoxic prostate cancer cells. Oncogene， 2007，26（52）：7333-7345.
|
| 10 |
Saijo Y， Tanaka M， Miki M， et al. Proinflammatory cytokine IL-1 beta promotes tumor growth of Lewis lung carcinoma by induction of angiogenic factors： in vivo analysis of tumorstromal interaction. J Immunol 2002，169（1）：469-475.
|
| 11 |
Jung YJ， Isaacs JS， Lee S， et al. IL-1beta-mediated upregulation of HIF-1alpha via an NFkappaB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis. FASEB J， 2003，17（14）：2115-2117.
|
| 12 |
Koh MY， Spivak-Kroizman TR， Powis G. HIF-1alpha and cancer therapy. Recent Results Cancer Res， 2010，180：15-34.
|
| 13 |
Mohamed KM， Le A， Duong H， et al. Correlation between VEGF and HIF-1alpha expression in human oral squamous cell carcinoma. Exp Mol Pathol， 2004，76（2）：143-152.
|
| 14 |
Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol， 2009，27：519-550.
|
| 15 |
Apte RN， Voronov E. Interleukin-1-a major pleiotropic cytokinein in tumor-host interactions. Semin Cancer Biol， 2002，12（4）：277-290.
|
| 16 |
Aqqarwal BB， Vijayalekshmi RV， Sung B. Targeting inflammatory pathways for prevention and therapy of cancer：short-term friend， long-term foe. Clin Cancer Res， 2009，15（2）：425-430.
|
| 17 |
Qin Y， Ekmekcioglu S， Liu P， et al. Constitutive aberrant endogenous interleukin-1 facilitates inflammation and growth in human melanoma. Mol Cancer Res， 2011，9（11）：1537-1550.
|
| 18 |
Wang L， Liu Z， Balivada S， et al. Interleukin-1β and transforming growth factor-β cooperate to induce neurosphere formation and increase tumorigenicity of adherent LN-229 glioma cells. Stem Cell Res Ther， 2012，3（1）：5.
|
| 19 |
Bouraoui Y， Ben Rais N， Culig Z， et al. Involvement of interleukin-1β mediated nuclear factor κB signalling pathways to down-regulate prostate-specific antigen and cell proliferation in LNCaP prostate cancer cells. Cell Biol Int， 2012，36（5）：449-454.
|
| 20 |
Carmi Y， Rinott G， Dotan S， et al. Microenvironment-derived IL-1 and IL-17 interact in the control of lung metastasis. J Immunol， 2011，186（6）：3462-3471.
|
| 21 |
Naldini A， Filippi I， Miglietta D， et al. Interleukin-1β regulates the migratory potential of MDAMB231 breast cancer cells through the hypoxia-inducible factor-1α. Eur J Cancer，2010，46（18）：3400-3408.
|
| 22 |
Björkdahl O， Dohlsten M， Sjögren HO. Vaccination with B16 melanoma cells expressing a secreted form of interleukin-1beta induces tumor growth inhibition and an enhanced immunity against the wild-type B16 tumor. Cancer Gene Ther， 2000，7（10）：1365-1374.
|
| 23 |
Chirivi RG， Garofalo A， Padura IM， et al. Interleukin 1 receptor antagonist inhibits the augmentation of metastasis induced by interleukin 1 or lipopolysaccharide in a human melanoma/nude mouse system. Cancer Res， 1993，53 （20）：5051-5054.
|
| 24 |
Krelin Y， Voronov E， Dotan S， et al. Interleukin-1β-driven inflammation promotes the development and invasiveness of chemical carcinogen-induced tumors. Cancer Res， 2007，67（3）：1062-1071.
|
| 25 |
Valastyan S， Weinberg RA. Tumor metastasis： molecular insights and evolving paradigms. Cell， 2011，147（2）：275-292.
|
| 26 |
Yoshiji H， Kuriyama S， Noguchi R， et al. Angiopoietin 2 displays a vascular endothelial growth factor dependent synergistic effect in hepatocellular carcinoma development in mice. Gut， 2005，54（12）：1768-1775.
|
| 27 |
Bar D， Apte RN， Voronov E， et al. A continuous delivery system of IL-1 receptor antagonist reduces angiogenesis and inhibits tumor development. FASEB J， 2004，18（1）：161-163.
|
| 28 |
Nakao S， Kuwano T， Tsutsumi-Miyahara C， et al. Infiltration of COX-2-expressing macrophages is a prerequisite for IL-1 beta-induced neovascularization and tumor growth. J Clin Invest， 2005，115（11）：2979-2991.
|
| 29 |
Gabellini C， Trisciuoglio D， Desideri M， et al. Functional activity of CXCL8 receptors， CXCR1 and CXCR2， on human malignant melanoma progression. Eur J Cancer， 2009，45（14）：2618-2627.
|
| 30 |
Varney ML， Singh S， Li A， et al. Small molecule antagonists for CXCR2 and CXCR1 inhibit human colon cancer liver metastases. Cancer Lett， 2011，300（2）：180-188.
|
| 31 |
徐文华，程继光，王元银. CXCR1、CXCR2 在口腔鳞癌中的表达及意义. 实用肿瘤杂志，2011，26（6）：618-621.
|
| 32 |
Neiva KG， Zhang Z， Miyazawa M， et al. Cross talk initiated by endothelial cells enhances migration and inhibits anoikis of squamous cell carcinoma cells through STAT3/Akt/ERK signaling. Neoplasia， 2009，11（6）：583-593.
|
| 33 |
Wolf JS， Chen Z， Dong G， et al. IL （interleukin）-1alpha promotes nuclear factor-kappaB and AP-1-induced IL-8 expression， cell survival， and proliferation in head and neck squamous cell carcinomas. Clin Cancer Res， 2001，7（6）：1812-1820.
|
| 34 |
Lin Q， Yun Z. Impact of the hypoxic tumor microenvironment on the regulation of cancer stem cell characteristics. Cancer Biol Ther， 2010，9（12）：949-956.
|
| 35 |
Poon E， Harris AL， Ashcroft M. Targeting the hypoxiainducible factor （HIF） pathway in cancer. Expert Rev Mol Med， 2009，11：e26.
|
| 36 |
Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer， 2003，3（10）：721-732.
|
| 37 |
Lu H， Liang K， Lu Y， et al. The anti-EGFR antibody cetuximab sensitizes human head and neck squamous cell carcinoma cells to radiation in part through inhibiting radiationinduced upregulation of HIF-1α. Cancer Lett， 2012 Feb 17.［Epub ahead of print］
|
| 38 |
Bernards R. Cancer： cues for migration. Nature， 2003，425（6955）：247-248.
|